--- title: "GNQ Insilico 計劃加速精準醫療和臨牀人工智能在藥物開發及患者護理中的應用" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/282902406.md" description: "GNQ Insilico，一家精準醫療科技生物公司，宣佈與 IBM 合作，通過其因果 AI 藥物評估、藥物模擬和數字雙胞胎平台來增強個性化醫療的採用。此次合作旨在通過整合 IBM 的諮詢和混合雲專業知識，降低臨牀試驗失敗率並改善治療決策。這些平台的目標是新興生物製藥公司、大型製藥組織和醫療系統。GNQ 已經獲得了一項 9600 萬美元的協議，以在北美健康項目中實施其數字雙胞胎平台，為該倡議帶來了顯著的商業動力" datetime: "2026-04-15T21:25:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282902406.md) - [en](https://longbridge.com/en/news/282902406.md) - [zh-HK](https://longbridge.com/zh-HK/news/282902406.md) --- # GNQ Insilico 計劃加速精準醫療和臨牀人工智能在藥物開發及患者護理中的應用 _The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms with IBM’s consulting and hybrid cloud expertise._ SAN JOSE, Calif.--(BUSINESS WIRE)-- GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine. Through this collaboration, GNQ will deliver its causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms supported by IBM’s consulting expertise and hybrid cloud deployment experience. The collaboration is formalized through a global Joint Initiative Marketing Agreement signed in March 2026. Clinical trial failure rates remain high, and treatment decisions are often made without full insight into individual patient biology. The platforms are designed to address these challenges by pairing GNQ’s mechanistic, causal AI models with IBM’s secured, scalable technology infrastructure, to support life sciences companies and healthcare providers in their efforts towards more predictive drug development and more personalized clinical decisions. The platform offerings are now available and are designed to support three primary groups: - Emerging biopharma companies looking to mitigate risk in early drug development. - Large pharmaceutical organizations seeking to improve and scale their clinical decision-making. - Hospitals and health systems aiming to deliver more personalized, data-driven support for treatment decisions. “GNQ's differentiation is our causal AI framework grounded in elementary reaction kinetics and pathway biology—modeling how therapies interact with individual patient biology at the mechanistic level through quantum-enhanced simulation. Our Biomedical Reasoning Model enables true causal inference, not just pattern recognition. IBM's Consulting’s enterprise AI platform, hybrid cloud infrastructure, and deep life sciences industry expertise provide the foundation to deploy this precision medicine platform at scale,” said Sudhir Saxena, Chief Technology Officer, GNQ Insilico, Inc. “We believe that AI-driven causal reasoning will define the future of drug development and precision medicine, and we are building that future.” **Combining Causal Reasoning AI with Enterprise Infrastructure** The offering integrates IBM’s consulting and hybrid cloud services with GNQ’s digital twin technology, which uses causal simulations and biological pathway modeling to inform how individual patients may respond to therapies. GNQ’s platform reasons from the physics of molecules to the fate of patients — encoding biology as quantitative cause-and-effect equations, grounding drug-target interactions in quantum simulation, and providing insights on each patient’s individual treatment future through a living causal model of their own biology. Together, the offering is being designed to help reduce clinical development risk, increase trial success probability, and help clinicians to make more personalized treatment decisions based on mechanistic biological insight. **Digital Twin Platforms in Action** The platforms are already generating commercial momentum. GNQ Insilico has signed a three-year, $96 million agreement with a physician-led comprehensive health program operating across North America. Under this agreement, GNQ’s Digital Twin Platforms will serve as the foundational clinical AI infrastructure for the program’s clinic network, enabling longitudinal, multi-omics-based health insights for physicians and patients. IBM is supporting GNQ through healthcare and life sciences consulting, hybrid cloud platform deployment, and systems integration for rapid rollout across clinic locations. The collaboration is intended to serve as a model for how combined causal AI and enterprise‑grade infrastructure can be deployed across functional medicine networks, provider groups, and health systems globally with the insights from GNQ AI Genomic platforms. “The life sciences and healthcare industries are at an inflection point. AI is no longer experimental — it is becoming important infrastructure for organizations working to reduce clinical failure rates and move from reactive to more proactive care,” said Manoj Kenkare, Senior Partner, Life Sciences Industry Leader, IBM Consulting. “GNQ Insilico brings something differentiated: mechanistic, causal intelligence grounded in pathway biology, rather than pattern matching on historical data. This collaboration brings together capabilities that are truly greater than the sum of their parts, and we see significant potential as we scale this across our global client relationships.” **About GNQ Insilico, Inc.** GNQ Insilico, Inc. is a California-based precision medicine TechBio company developing quantum-enhanced AI platforms for drug assessment, clinical decision support, and personalized medicine. GNQ’s platform stack encompasses the Drug Assessment Platform (DAP), the Drug Simulation Platform (DSP), the Digital Twin Platform (DTP), and the Biomedical Reasoning Model (BRM) — all grounded in causal inference, pathway biology, and quantum molecular simulation. Website: gnq.ai _Forward-Looking Statements: This press release contains forward-looking statements based on current expectations. Actual results may differ materially. GNQ Insilico assumes no obligation to update these statements. IBM and GNQ Insilico are independent parties. The collaboration described herein does not constitute a legal partnership. Financial transactions for specific engagements are governed by separate agreements between the parties._ View source version on businesswire.com: https://www.businesswire.com/news/home/20260415653549/en/ Source: GNQ Insilico, Inc. ### 相關股票 - [000863.CN](https://longbridge.com/zh-HK/quote/000863.CN.md) - [IBM.US](https://longbridge.com/zh-HK/quote/IBM.US.md) ## 相關資訊與研究 - [核心醫療累虧超 4 億：產品單價下行，遞表前五次股權轉讓價劇烈波動](https://longbridge.com/zh-HK/news/286981242.md) - [工研院串聯跨法人能量 打造國家藥物韌性防線](https://longbridge.com/zh-HK/news/287186590.md) - [美國 FDA 測試即時取得臨牀試驗資料，以利加速藥物審核](https://longbridge.com/zh-HK/news/286686699.md) - [快閃英法參訪...歐洲在宅醫療模式大開眼界 石崇良：進速升級長照 3.0](https://longbridge.com/zh-HK/news/286931217.md) - [保柏：港人深圳求醫年 70 萬人次](https://longbridge.com/zh-HK/news/286818539.md)